EGFR and neoplasm: Adnectin monobodies were introduced into CAR-T systems to target tumours overexpressing VEGFR2 or EGFR [53,94], and through reducing affinity to EGFR the CAR-T cells were engineered to only reach effective concentrations at tumour cells which drastically over-express the target receptor.